Literature DB >> 11131147

Alpha1-antichymotrypsin and kallistatin hydrolysis by human cathepsin D.

D C Pimenta1, V C Chen, J Chao, M A Juliano, L Juliano.   

Abstract

In the present paper, we demonstrate that alpha1-antichymotrypsin, a serpin with high inhibitory specificity toward cathepsin G, and kallistatin, a human serpin with high specificity toward tissue kallikrein, are digested by cathepsin D. Alpha1-Antichymotrypsin was hydrolyzed essentially in the reactive center loop at L-S, A-L, or L-V bonds; kallistatin was split into small fragments, but we detected the cleavage at F-F and F-S bonds in its reactive center loop in the first 15 min of digestion. In contrast to alpha1-antichymotrypsin, kallistatin is irreversibly inactivated at pH 4.0. Synthetic internally quenched fluorescent peptides containing sequences similar to the reactive center loops of these serpins were hydrolyzed by cathepsin D. The peptides derived from kallistatin were hydrolyzed more efficiently, and particularly relevant was the high susceptibility of the substrates Abz-AIKFFSAQTNRHILRFNRQ-EDDnp (Km = 0.08 microM, kcat = 2.4 s(-1)) and Abz-AIKFFSAQTNRQ-EDDnp (Km = 0.8 microM, kcat = 17.8 s(-1)), which were hydrolyzed at the F-F bond. Therefore, besides the description of a new class of very efficient internally quenched substrates for cathepsin D, we give evidence for the downregulation role of this proteinase on alpha1-antichymotrypsin and kallistatin. The acidification of extracellular milieu by tumor cells can result in activation of cathepsin D; as a consequence, kinins can be released, improving blood supply and leaving more cathepsin G available for the degradation of extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11131147     DOI: 10.1023/a:1026432402259

Source DB:  PubMed          Journal:  J Protein Chem        ISSN: 0277-8033


  50 in total

1.  Bradykinin B(2) receptor-mediated mitogen-activated protein kinase activation in COS-7 cells requires dual signaling via both protein kinase C pathway and epidermal growth factor receptor transactivation.

Authors:  A Adomeit; A Graness; S Gross; K Seedorf; R Wetzker; C Liebmann
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

Review 2.  Lysosomes.

Authors:  R T Dean; A J Barrett
Journal:  Essays Biochem       Date:  1976       Impact factor: 8.000

3.  An increase of cathepsin D activity in cardiac lymph and pericadial fluid induced by experimental myocardial ischemia in the dog.

Authors:  H Araki; F Takenaka
Journal:  Life Sci       Date:  1975-08-15       Impact factor: 5.037

4.  Statistical estimations in enzyme kinetics.

Authors:  G N WILKINSON
Journal:  Biochem J       Date:  1961-08       Impact factor: 3.857

5.  Mitogenic activation of human prostate-derived fibromuscular stromal cells by bradykinin.

Authors:  P D Walden; G K Lefkowitz; M Ittmann; H Lepor; M E Monaco
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

6.  Acid optimum kininogenases in canine myocardium and aorta.

Authors:  M J Moshi; I J Zeitlin; C L Wainwright; J R Parratt
Journal:  Cardiovasc Res       Date:  1992-04       Impact factor: 10.787

Review 7.  Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview.

Authors:  H Rochefort; M Garcia; M Glondu; V Laurent; E Liaudet; J M Rey; P Roger
Journal:  Clin Chim Acta       Date:  2000-02-15       Impact factor: 3.786

8.  Activation of mitogen-activated protein kinase by the bradykinin B2 receptor is independent of receptor phosphorylation and phosphorylation-triggered internalization.

Authors:  A Blaukat; A Pizard; R M Rajerison; F Alhenc-Gelas; W Müller-Esterl; I Dikic
Journal:  FEBS Lett       Date:  1999-05-28       Impact factor: 4.124

9.  Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence.

Authors:  G X Zhou; L Chao; J Chao
Journal:  J Biol Chem       Date:  1992-12-25       Impact factor: 5.157

10.  Role of cathepsin D in antigen presentation of ovalbumin.

Authors:  G M Rodriguez; S Diment
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

View more
  6 in total

1.  Apolipoprotein A1 and C-terminal fragment of α-1 antichymotrypsin are candidate plasma biomarkers associated with acute renal allograft rejection.

Authors:  Mary E Ziegler; Tingchao Chen; James F LeBlanc; Xuelian Wei; David W Gjertson; Ker-Chau Li; Mazdak A Khalighi; Charles R Lassman; Jeffrey L Veale; H Albin Gritsch; Elaine F Reed
Journal:  Transplantation       Date:  2011-08-27       Impact factor: 4.939

Review 2.  Adamantinomatous craniopharyngioma: advances in proteomic research.

Authors:  Claudia Desiderio; Diana Valeria Rossetti; Massimo Castagnola; Luca Massimi; Gianpiero Tamburrini
Journal:  Childs Nerv Syst       Date:  2020-07-02       Impact factor: 1.475

Review 3.  Cathepsin D--many functions of one aspartic protease.

Authors:  Petr Benes; Vaclav Vetvicka; Martin Fusek
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-08       Impact factor: 6.312

4.  Investigating the Protein Signature of Adamantinomatous Craniopharyngioma Pediatric Brain Tumor Tissue: Towards the Comprehension of Its Aggressive Behavior.

Authors:  Claudia Martelli; Riccardo Serra; Ilaria Inserra; Diana Valeria Rossetti; Federica Iavarone; Federica Vincenzoni; Massimo Castagnola; Andrea Urbani; Gianpiero Tamburrini; Massimo Caldarelli; Luca Massimi; Claudia Desiderio
Journal:  Dis Markers       Date:  2019-05-02       Impact factor: 3.434

5.  Proteolytic characteristics of cathepsin D related to the recognition and cleavage of its target proteins.

Authors:  Huiying Sun; Xiaomin Lou; Qiang Shan; Ju Zhang; Xu Zhu; Jia Zhang; Yang Wang; Yingying Xie; Ningzhi Xu; Siqi Liu
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

6.  Nanomedical strategy to prolong survival period, heighten cure rate, and lower systemic toxicity of S180 mice treated with MTX/MIT.

Authors:  Ning Song; Ming Zhao; Yuji Wang; Xi Hu; Jianhui Wu; Xueyun Jiang; Shan Li; Chunying Cui; Shiqi Peng
Journal:  Drug Des Devel Ther       Date:  2016-08-30       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.